PUBLICATIONS

Explore our posters and presentations.

We are passionate about our mission to cure HBV, as well as our voice in the scientific community. That’s why we regularly publish meaningful content on our dynamic pipeline of therapeutics. Explore our scientific publications by format or asset.

Arbutus Publications
Presentation | June 6, 2024

Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone

Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone
Poster | June 5, 2024

Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment

Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
Presentation | April 2, 2024

Curing Chronic Viral Hepatitis: A Story of Transformational Success and Another of Enduring Hope

Curing Chronic Viral Hepatitis: A Story of Transformational Success and Another of Enduring Hope
Presentation | February 21, 2024

Manuscript: Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161

Manuscript: Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161
Presentation | December 5, 2023

Progress towards a functional cure for hepatitis B

Progress towards a functional cure for hepatitis B
Poster | December 5, 2023

The RNA Interference Therapeutic Imdusiran Retains Activity Against HBsAg in Chronic Hepatitis B Subjects with Baseline Nucleotide Polymorphisms Within the HBV Target Site

The RNA Interference Therapeutic Imdusiran Retains Activity Against HBsAg in Chronic Hepatitis B Subjects with Baseline Nucleotide Polymorphisms Within the HBV Target Site
Poster | November 9, 2023

Preliminary pharmacodynamics and safety of repeat dosing of imdusiran (AB-729) followed by VTP-300 or placebo in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)

Preliminary pharmacodynamics and safety of repeat dosing of imdusiran (AB-729) followed by VTP-300 or placebo in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)
Poster | November 9, 2023

Baseline nucleotide polymorphisms within HBV target site in chronic hepatitis B subjects do not impact HBsAg reductions mediated by RNA interference therapeutic Imdusiran (AB-729)

Baseline nucleotide polymorphisms within HBV target site in chronic hepatitis B subjects do not impact HBsAg reductions mediated by RNA interference therapeutic Imdusiran (AB-729)
Poster | November 9, 2023

Oral Small-Molecule Liver-Tropic PD-L1 Inhibitor Pharmacokinetics for the Treatment of Hepatocellular Carcinoma

Oral Small-Molecule Liver-Tropic PD-L1 Inhibitor Pharmacokinetics for the Treatment of Hepatocellular Carcinoma
Presentation | November 8, 2023

Imdusiran: Sustained HBsAg Suppression and Host Immune Control

Imdusiran: Sustained HBsAg Suppression and Host Immune Control
Poster | June 21, 2023

Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
Poster | June 21, 2023

Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836

Hepatitis B virus core protein variant profiles observed in chronic hepatitis B patients treated with capsid inhibitor AB-836
Presentation | June 2, 2023

Update on AB-729, an RNAi therapeutic in Phase 2 development as a key component of a functional cure strategy for cHBV

Update on AB-729, an RNAi therapeutic in Phase 2 development as a key component of a functional cure strategy for cHBV
Poster | May 3, 2023

Biochemical characterization of AB-343, a novel, potent, and orally bioavailable SARS-CoV-2 main protease inhibitor with a pan-coronavirus profile

Biochemical characterization of AB-343, a novel, potent, and orally bioavailable SARS-CoV-2 main protease inhibitor with a pan-coronavirus profile
Presentation | April 27, 2023

48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy

48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy
Presentation | April 27, 2023

Preclinical Antiviral Profiling of AB-161, an Oral HBV Inhibitor that Destabilizes HBV RNA and Suppresses HBsAg

Preclinical Antiviral Profiling of AB-161, an Oral HBV Inhibitor that Destabilizes HBV RNA and Suppresses HBsAg
Poster | March 14, 2023

In Vitro Antiviral Profile of AB-343, a Novel, Oral, Potent SARS-CoV-2 Mpro Inhibitor with Pan-coronavirus Activity

In Vitro Antiviral Profile of AB-343, a Novel, Oral, Potent SARS-CoV-2 Mpro Inhibitor with Pan-coronavirus Activity
Presentation | November 2, 2022

Evidence of T Cell Restoration after siRNA Therapy

Evidence of T Cell Restoration after siRNA Therapy
Poster | November 1, 2022

Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy

Hepatitis B viral control maintained during extended follow up of HBeAg- chronic hepatitis B (CHB) subjects who discontinued nucleos(t)ide analogue (NA) therapy after completion of AB-729 treatment, and in HBeAg+ subjects still on NA therapy
Poster | November 1, 2022

Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model

Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model
Poster | November 1, 2022

Evaluation of the Vebicorvir, NRTI and AB-729 Combination in virologically Suppressed Patients with HBeAg Negative Chronic Hepatitis B Virus Infection: Interim Analysis from an Open Label Phase 2 Study

Evaluation of the Vebicorvir, NRTI and AB-729 Combination in virologically Suppressed Patients with HBeAg Negative Chronic Hepatitis B Virus Infection: Interim Analysis from an Open Label Phase 2 Study
Poster | November 1, 2022

Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model

Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model
Presentation | October 19, 2022

AB-161, an Oral HBV RNA Destabilizer to Suppress HBV RNA and HBsAg

AB-161, an Oral HBV RNA Destabilizer to Suppress HBV RNA and HBsAg
Presentation | September 22, 2022

Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model

Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model
Poster | June 25, 2022

Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729

Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729
Poster | June 25, 2022

Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects

Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects
Poster | June 25, 2022

Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver

Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver
Poster | June 25, 2022

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects
Poster | June 25, 2022

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells
Poster | June 25, 2022

Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients

Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients
Poster | March 11, 2022

Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers from DHQ and THP Chemical Series

International Conference on Antiviral Research (ICAR)

Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers from DHQ and THP Chemical Series
Presentation | December 7, 2021

Progress Toward an HBV Cure Combination Therapy

Hep DART 2021

Progress Toward an HBV Cure Combination Therapy
Poster | November 12, 2021

Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy 

Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy 
Presentation | October 11, 2021

Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection

The Science of HBV Cure Meeting 2021 (Virtual)

Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection
Poster | September 26, 2021

Kinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agents

2021 International HBV Meeting

Kinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agents
Presentation | June 28, 2021

Clinical Update Based on Data Presented at the EASL International Liver Congress™ 2021

EASL International Liver Congress™ 2021

Clinical Update Based on Data Presented at the EASL International Liver Congress™ 2021
Poster | June 23, 2021

Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers

EASL International Liver Congress™ 2021

Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers
Poster | June 23, 2021

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA

EASL International Liver Congress™ 2021

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA
Poster | June 23, 2021

A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infection

EASL International Liver Congress™ 2021

A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infection
Presentation | June 23, 2021

Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression

EASL International Liver Congress™ 2021

Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Presentation | May 5, 2021

An RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical Update

Chronic Hepatitis B Drug Development Summit

An RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical Update
Presentation | February 4, 2021

AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021

AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021
Presentation | November 16, 2020

AB-729 Clinical Update 

AB-729 Clinical Update 
Presentation | November 15, 2020

Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection

The Liver Meeting Digital Experience™ | AASLD

Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection
Presentation | May 18, 2020

AB-729 Clinical Update

AB-729 Clinical Update
Presentation | March 26, 2020

AB-729 Clinical Update

AB-729 Clinical Update
Suppress Reduce Boost

HBV

Learn about our three-pronged Suppress, Reduce, Boost approach to HBV.

Discover Our HBV Assets

Pan Coronavirus Treatment

Coronavirus

Learn more about how we are innovating in pan-coronavirus treatment.

Discover Our Coronavirus Assets